Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Prostate Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Metastatic Prostate Cancer - Pipeline Review, H1 2015', provides an overview of the Metastatic Prostate Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Metastatic Prostate Cancer Overview 8 Therapeutics Development 9 Pipeline Products for Metastatic Prostate Cancer - Overview 9 Pipeline Products for Metastatic Prostate Cancer - Comparative Analysis 10 Metastatic Prostate Cancer - Therapeutics under Development by Companies 11 Metastatic Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 13 Metastatic Prostate Cancer - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Metastatic Prostate Cancer - Products under Development by Companies 17 Metastatic Prostate Cancer - Products under Investigation by Universities/Institutes 18 Metastatic Prostate Cancer - Companies Involved in Therapeutics Development 19 Actinium Pharmaceuticals, Inc. 19 Camurus AB 20 Colby Pharmaceutical Company 21 Eli Lilly and Company 22 Fountain Biopharma Inc. 23 Johnson & Johnson 24 MedImmune, LLC 25 MEI Pharma, Inc. 26 OncoMax 27 OXiGENE, Inc. 28 Progenics Pharmaceuticals, Inc. 29 ValiRx Plc 30 Metastatic Prostate Cancer - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 abiraterone acetate - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Actimab-P - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 CADD-522 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Cell Therapy to Target PSMA for Metastatic Prostate Cancer - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 CPC-410 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 FB-704A - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 KGP-94 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 leuprolide acetate - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 LU-901 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 LY-2495655 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 MEDI-6469 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 MIP-1095 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 MVI-118 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 OMRCA-01 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 pracinostat - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Recombinant Protein for Oncology - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 VAC-1 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 VAL-201 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Metastatic Prostate Cancer - Recent Pipeline Updates 65 Metastatic Prostate Cancer - Dormant Projects 75 Metastatic Prostate Cancer - Discontinued Products 76 Metastatic Prostate Cancer - Product Development Milestones 77 Featured News & Press Releases 77 Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference 77 Feb 06, 2014: ZYTIGA Now Reimbursed in Quebec for Use Prior to Chemotherapy in Men with Metastatic Prostate Cancer 77 Nov 21, 2013: ZYTIGA Now Available for Men with Metastatic Prostate Cancer in British Columbia Prior to Chemotherapy 78 May 29, 2013: Janssen's Zytiga Receives New Indication Approval From Health Canada For Treatment Of Metastatic Prostate Cancer 78 Jun 02, 2012: Zytiga's Phase III Results Show Significant Improvement In Radiographic Progression-Free Survival And Trend For Increased Overall Survival In Metastatic Prostate Cancer Patients 80 May 16, 2012: J&J's ZYTIGA Now Available For Eligible Patients In Nova Scotia, Newfoundland And Labrador For Prostate Cancer 81 Mar 04, 2005: Geron Announces Publication Of Phase 1-2 Telomerase Vaccine Study Results In Patients With Metastatic Prostate Cancer 81 Appendix 83 Methodology 83 Coverage 83 Secondary Research 83 Primary Research 83 Expert Panel Validation 83 Contact Us 84 Disclaimer 84
List of Tables Number of Products under Development for Metastatic Prostate Cancer, H1 2015 9 Number of Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Number of Products under Investigation by Universities/Institutes, H1 2015 13 Comparative Analysis by Late Stage Development, H1 2015 14 Comparative Analysis by Clinical Stage Development, H1 2015 15 Comparative Analysis by Early Stage Development, H1 2015 16 Products under Development by Companies, H1 2015 17 Products under Investigation by Universities/Institutes, H1 2015 18 Metastatic Prostate Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 19 Metastatic Prostate Cancer - Pipeline by Camurus AB, H1 2015 20 Metastatic Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H1 2015 21 Metastatic Prostate Cancer - Pipeline by Eli Lilly and Company, H1 2015 22 Metastatic Prostate Cancer - Pipeline by Fountain Biopharma Inc., H1 2015 23 Metastatic Prostate Cancer - Pipeline by Johnson & Johnson, H1 2015 24 Metastatic Prostate Cancer - Pipeline by MedImmune, LLC, H1 2015 25 Metastatic Prostate Cancer - Pipeline by MEI Pharma, Inc., H1 2015 26 Metastatic Prostate Cancer - Pipeline by OncoMax, H1 2015 27 Metastatic Prostate Cancer - Pipeline by OXiGENE, Inc., H1 2015 28 Metastatic Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H1 2015 29 Metastatic Prostate Cancer - Pipeline by ValiRx Plc, H1 2015 30 Assessment by Monotherapy Products, H1 2015 31 Number of Products by Stage and Target, H1 2015 33 Number of Products by Stage and Mechanism of Action, H1 2015 35 Number of Products by Stage and Route of Administration, H1 2015 37 Number of Products by Stage and Molecule Type, H1 2015 39 Metastatic Prostate Cancer Therapeutics - Recent Pipeline Updates, H1 2015 65 Metastatic Prostate Cancer - Dormant Projects, H1 2015 75 Metastatic Prostate Cancer - Discontinued Products, H1 2015 76
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
